Skip to main content

Table 3 Correlation of BRAF IHC results and clinicopathological characteristics

From: Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

  BRAF IHC  
Characteristics NEGATIVE (N = 29) POSITIVE (N = 34) p value
Sex
 Male 20 (68.97) 15 (44.12) 0.0479*
 Female 9 (31.03) 19 (55.88)  
Age
  64.55 ± 12.94 51.18 ± 15.33 0.001*
Stage at diagnosis
 I + II 7 (24.14) 12 (36.36) 0.2975
 III + IV 22 (75.86) 21 (63.64)  
Metastatic stage
 M1a 8 (27.59) 5 (14.71) 0.0564
 M1b 1 (3.45) 8 (23.53)  
 M1c 20 (68.97) 21 (61.76)  
Brain metastasis
 No 20 (68.97) 21 (61.76) 0.5501
 Yes 9 (31.03) 13 (38.24)  
N° metastasis
  ≤ 2 13 (44.83) 15 (44.12) 0.9549
  > 2 16 (55.17) 19 (55.88)  
  1. *p < 0.005